Moderna Inc (MRNA)
137.71
-4.57 (-3.21%)
USD |
NASDAQ |
May 18, 16:00
138.16
+0.45 (+0.33%)
After-Hours: 04:20
Moderna Cash from Financing (TTM): -1.541B for March 31, 2022
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2022 | -1.541B |
December 31, 2021 | -873.00M |
September 30, 2021 | 44.00M |
June 30, 2021 | 76.00M |
March 31, 2021 | 1.481B |
December 31, 2020 | 2.033B |
September 30, 2020 | 2.021B |
Date | Value |
---|---|
June 30, 2020 | 2.007B |
March 31, 2020 | 629.71M |
December 31, 2019 | 52.00M |
September 30, 2019 | 596.20M |
June 30, 2019 | 570.96M |
March 31, 2019 | 677.14M |
December 31, 2018 | 1.227B |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-1.541B
Minimum
Mar 2022
2.033B
Maximum
Dec 2020
642.86M
Average
612.95M
Median
Cash from Financing (TTM) Benchmarks
Regeneron Pharmaceuticals Inc | -574.70M |
Vertex Pharmaceuticals Inc | -1.055B |
Arbutus Biopharma Corp | 121.85M |
Johnson & Johnson | -13.31B |
Merck & Co Inc | 1.605B |